282 related articles for article (PubMed ID: 26812426)
21. Effects of Glycan Structure on the Stability and Receptor Binding of an IgG4-Fc.
Kang H; Larson NR; White DR; Middaugh CR; Tolbert T; Schöneich C
J Pharm Sci; 2020 Jan; 109(1):677-689. PubMed ID: 31669606
[TBL] [Abstract][Full Text] [Related]
22. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic.
Barb AW; Prestegard JH
Nat Chem Biol; 2011 Mar; 7(3):147-53. PubMed ID: 21258329
[TBL] [Abstract][Full Text] [Related]
23. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
24. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
25. Naturally occurring glycan forms of human immunoglobulins G1 and G2.
Flynn GC; Chen X; Liu YD; Shah B; Zhang Z
Mol Immunol; 2010 Jul; 47(11-12):2074-82. PubMed ID: 20444501
[TBL] [Abstract][Full Text] [Related]
26. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins.
Ahmed AA; Giddens J; Pincetic A; Lomino JV; Ravetch JV; Wang LX; Bjorkman PJ
J Mol Biol; 2014 Sep; 426(18):3166-3179. PubMed ID: 25036289
[TBL] [Abstract][Full Text] [Related]
27. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
28. Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC.
Raju TS
Methods Mol Biol; 2013; 988():169-80. PubMed ID: 23475719
[TBL] [Abstract][Full Text] [Related]
29. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
[TBL] [Abstract][Full Text] [Related]
30. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
31. The effect of Fc glycan forms on human IgG2 antibody clearance in humans.
Chen X; Liu YD; Flynn GC
Glycobiology; 2009 Mar; 19(3):240-9. PubMed ID: 18974198
[TBL] [Abstract][Full Text] [Related]
32. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
Lee HS; Im W
Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
[TBL] [Abstract][Full Text] [Related]
33. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
[TBL] [Abstract][Full Text] [Related]
34. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence.
Lundström SL; Fernandes-Cerqueira C; Ytterberg AJ; Ossipova E; Hensvold AH; Jakobsson PJ; Malmström V; Catrina AI; Klareskog L; Lundberg K; Zubarev RA
PLoS One; 2014; 9(11):e113924. PubMed ID: 25426976
[TBL] [Abstract][Full Text] [Related]
35. Sequence-to-structure dependence of isolated IgG Fc complex biantennary N-glycans: a molecular dynamics study.
Harbison AM; Brosnan LP; Fenlon K; Fadda E
Glycobiology; 2019 Jan; 29(1):94-103. PubMed ID: 30325416
[TBL] [Abstract][Full Text] [Related]
36. Conformational analysis of g protein-coupled receptor signaling by hydrogen/deuterium exchange mass spectrometry.
Li S; Lee SY; Chung KY
Methods Enzymol; 2015; 557():261-78. PubMed ID: 25950969
[TBL] [Abstract][Full Text] [Related]
37. In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase.
Warnock D; Bai X; Autote K; Gonzales J; Kinealy K; Yan B; Qian J; Stevenson T; Zopf D; Bayer RJ
Biotechnol Bioeng; 2005 Dec; 92(7):831-42. PubMed ID: 16187338
[TBL] [Abstract][Full Text] [Related]
38. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
[TBL] [Abstract][Full Text] [Related]
39. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
[TBL] [Abstract][Full Text] [Related]
40. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
